• Profile
Close

Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis

JAMA Jan 18, 2019

Brown JWL, et al. - Investigators assessed 1,555 patients with relapsing-remitting multiple sclerosis (MS) to examine the relationship between the application, the type of, and the timing of disease-modifying treatments (DMTs) with the risk of conversion to secondary progressive multiple sclerosis (MS). They observed initial treatment with fingolimod, alemtuzumab, or natalizumab linked to a lower risk of conversion to secondary progressive MS vs initial treatment with glatiramer acetate or interferon beta among these patients. They noticed that considering the outcome obtained along with the risk of such treatments might prove beneficial during making decisions about DMT selection.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay